TGF-alpha as a candidate tumor antigen for renal cell carcinomas

Sandy Pelletier, Simon Tanguay, Stephen Lee, Lakshman Gunaratnam, Nathalie Arbour, Réjean Lapointe

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Objectives: Patients with renal cell carcinomas (RCC) have few treatment options, underscoring the importance of developing new approaches such as immunotherapy. However, few tumor associated antigens (TAA), which can be targeted by immunotherapy, have been identified for this type of cancer. von Hippel-Lindau clear cell RCC (VHL-/-RCC) are characterized by mutations in the VHL tumor suppressor gene. Loss of VHL function causes the overexpression of transforming growth factor (TGF)-α, leading us to hypothesize that TGF-α could be a potential TAA for immunotherapy of kidney cancer, which was evaluated in this study. Methods and results: We first confirmed the absent or weak expression of TGF-α in important normal tissues as well as its overexpression in 61% of renal tumors in comparison to autologous normal kidney tissues. In addition, we demonstrated the immunogenicity of TGF-α, by expanding many T cell lines specific for certain TGF-α peptides or the mature TGF-α protein, when presented by major histocompatibility complex (MHC) molecules on the surface of antigen-presenting cells. Interestingly, some of these TGF-α-specific T cells were polyfunctionals and secreted IFN-γ, TNF-α and IL-2. Conclusion: We have shown that TGF-α is a valid candidate TAA, which should allow the development of a targeted immunotherapy.

Original languageEnglish (US)
Pages (from-to)1207-1218
Number of pages12
JournalCancer Immunology, Immunotherapy
Volume58
Issue number8
DOIs
StatePublished - Aug 2009
Externally publishedYes

Fingerprint

Transforming Growth Factor alpha
Transforming Growth Factors
Neoplasm Antigens
Renal Cell Carcinoma
Immunotherapy
T-Lymphocytes
Kidney
Kidney Neoplasms
Antigen-Presenting Cells
Surface Antigens
Major Histocompatibility Complex
Tumor Suppressor Genes
Interleukin-2
Neoplasms
Cell Line
Peptides
Mutation

Keywords

  • Cancer immunotherapy
  • Clear cell renal cell carcinoma
  • Polyfunctional antigen-specific T lymphocytes
  • Transforming growth factor (TGF)-α
  • Tumor antigen

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Immunology
  • Immunology and Allergy

Cite this

Pelletier, S., Tanguay, S., Lee, S., Gunaratnam, L., Arbour, N., & Lapointe, R. (2009). TGF-alpha as a candidate tumor antigen for renal cell carcinomas. Cancer Immunology, Immunotherapy, 58(8), 1207-1218. https://doi.org/10.1007/s00262-008-0630-2

TGF-alpha as a candidate tumor antigen for renal cell carcinomas. / Pelletier, Sandy; Tanguay, Simon; Lee, Stephen; Gunaratnam, Lakshman; Arbour, Nathalie; Lapointe, Réjean.

In: Cancer Immunology, Immunotherapy, Vol. 58, No. 8, 08.2009, p. 1207-1218.

Research output: Contribution to journalArticle

Pelletier, S, Tanguay, S, Lee, S, Gunaratnam, L, Arbour, N & Lapointe, R 2009, 'TGF-alpha as a candidate tumor antigen for renal cell carcinomas', Cancer Immunology, Immunotherapy, vol. 58, no. 8, pp. 1207-1218. https://doi.org/10.1007/s00262-008-0630-2
Pelletier, Sandy ; Tanguay, Simon ; Lee, Stephen ; Gunaratnam, Lakshman ; Arbour, Nathalie ; Lapointe, Réjean. / TGF-alpha as a candidate tumor antigen for renal cell carcinomas. In: Cancer Immunology, Immunotherapy. 2009 ; Vol. 58, No. 8. pp. 1207-1218.
@article{00d86a2f1c3f41d387fae06b20ea9635,
title = "TGF-alpha as a candidate tumor antigen for renal cell carcinomas",
abstract = "Objectives: Patients with renal cell carcinomas (RCC) have few treatment options, underscoring the importance of developing new approaches such as immunotherapy. However, few tumor associated antigens (TAA), which can be targeted by immunotherapy, have been identified for this type of cancer. von Hippel-Lindau clear cell RCC (VHL-/-RCC) are characterized by mutations in the VHL tumor suppressor gene. Loss of VHL function causes the overexpression of transforming growth factor (TGF)-α, leading us to hypothesize that TGF-α could be a potential TAA for immunotherapy of kidney cancer, which was evaluated in this study. Methods and results: We first confirmed the absent or weak expression of TGF-α in important normal tissues as well as its overexpression in 61{\%} of renal tumors in comparison to autologous normal kidney tissues. In addition, we demonstrated the immunogenicity of TGF-α, by expanding many T cell lines specific for certain TGF-α peptides or the mature TGF-α protein, when presented by major histocompatibility complex (MHC) molecules on the surface of antigen-presenting cells. Interestingly, some of these TGF-α-specific T cells were polyfunctionals and secreted IFN-γ, TNF-α and IL-2. Conclusion: We have shown that TGF-α is a valid candidate TAA, which should allow the development of a targeted immunotherapy.",
keywords = "Cancer immunotherapy, Clear cell renal cell carcinoma, Polyfunctional antigen-specific T lymphocytes, Transforming growth factor (TGF)-α, Tumor antigen",
author = "Sandy Pelletier and Simon Tanguay and Stephen Lee and Lakshman Gunaratnam and Nathalie Arbour and R{\'e}jean Lapointe",
year = "2009",
month = "8",
doi = "10.1007/s00262-008-0630-2",
language = "English (US)",
volume = "58",
pages = "1207--1218",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "8",

}

TY - JOUR

T1 - TGF-alpha as a candidate tumor antigen for renal cell carcinomas

AU - Pelletier, Sandy

AU - Tanguay, Simon

AU - Lee, Stephen

AU - Gunaratnam, Lakshman

AU - Arbour, Nathalie

AU - Lapointe, Réjean

PY - 2009/8

Y1 - 2009/8

N2 - Objectives: Patients with renal cell carcinomas (RCC) have few treatment options, underscoring the importance of developing new approaches such as immunotherapy. However, few tumor associated antigens (TAA), which can be targeted by immunotherapy, have been identified for this type of cancer. von Hippel-Lindau clear cell RCC (VHL-/-RCC) are characterized by mutations in the VHL tumor suppressor gene. Loss of VHL function causes the overexpression of transforming growth factor (TGF)-α, leading us to hypothesize that TGF-α could be a potential TAA for immunotherapy of kidney cancer, which was evaluated in this study. Methods and results: We first confirmed the absent or weak expression of TGF-α in important normal tissues as well as its overexpression in 61% of renal tumors in comparison to autologous normal kidney tissues. In addition, we demonstrated the immunogenicity of TGF-α, by expanding many T cell lines specific for certain TGF-α peptides or the mature TGF-α protein, when presented by major histocompatibility complex (MHC) molecules on the surface of antigen-presenting cells. Interestingly, some of these TGF-α-specific T cells were polyfunctionals and secreted IFN-γ, TNF-α and IL-2. Conclusion: We have shown that TGF-α is a valid candidate TAA, which should allow the development of a targeted immunotherapy.

AB - Objectives: Patients with renal cell carcinomas (RCC) have few treatment options, underscoring the importance of developing new approaches such as immunotherapy. However, few tumor associated antigens (TAA), which can be targeted by immunotherapy, have been identified for this type of cancer. von Hippel-Lindau clear cell RCC (VHL-/-RCC) are characterized by mutations in the VHL tumor suppressor gene. Loss of VHL function causes the overexpression of transforming growth factor (TGF)-α, leading us to hypothesize that TGF-α could be a potential TAA for immunotherapy of kidney cancer, which was evaluated in this study. Methods and results: We first confirmed the absent or weak expression of TGF-α in important normal tissues as well as its overexpression in 61% of renal tumors in comparison to autologous normal kidney tissues. In addition, we demonstrated the immunogenicity of TGF-α, by expanding many T cell lines specific for certain TGF-α peptides or the mature TGF-α protein, when presented by major histocompatibility complex (MHC) molecules on the surface of antigen-presenting cells. Interestingly, some of these TGF-α-specific T cells were polyfunctionals and secreted IFN-γ, TNF-α and IL-2. Conclusion: We have shown that TGF-α is a valid candidate TAA, which should allow the development of a targeted immunotherapy.

KW - Cancer immunotherapy

KW - Clear cell renal cell carcinoma

KW - Polyfunctional antigen-specific T lymphocytes

KW - Transforming growth factor (TGF)-α

KW - Tumor antigen

UR - http://www.scopus.com/inward/record.url?scp=67349208136&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349208136&partnerID=8YFLogxK

U2 - 10.1007/s00262-008-0630-2

DO - 10.1007/s00262-008-0630-2

M3 - Article

C2 - 19052740

AN - SCOPUS:67349208136

VL - 58

SP - 1207

EP - 1218

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 8

ER -